1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Nanexa AB (publ)

Nanexa AB (publ)

NANEXA.ST
Nanexa AB (publ)SE flagStockholm Stock Exchange
3.56
SEK
-0.08
- -
585.92MMarket Cap
Nanexa AB (publ)
NANEXA.ST
(Stockholm Stock Exchange)

Recent

price

3.56

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
0.12
0.04
0.01
0.03
0.11
0.12
0.07
0.06
0.42
0.18
0.23
0.22
Revenue per Share
- -
-0.74
-0.92
-0.65
-0.91
-0.82
-1.09
-1.01
-1.16
-1.09
-0.18
-0.07
-0.1
Basic EPS, GAAP
- -
-0.9
-1.28
-0.94
-1.09
-1.27
-1.89
-1.43
-0.85
-1.1
-0.4
-0.17
-0.15
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-1.41
-2.27
-2.11
-3.27
-3.68
-4.77
-3.89
-4.25
-3.66
-2.2
-2.05
-2.06
Book Value per Share
- -
0.41
1.73
1.63
0.43
0.5
0.49
2.96
0.86
0.79
0.08
0.17
0.31
Tangible Book Value per Share
- -
6
7
12
12
16
20
36
51
70
136
156
162
Basic Weighted Avg Shares
- -
1
- -
- -
- -
2
2
2
3
29
24
36
35
Sales/Revenue/Turnover
- -
-607.93
-2,253.16
-7,447.52
-3,456.74
-741.4
-896.7
-1,503.12
-2,038.5
-260.29
-108.28
-22.96
-40.59
Operating Margin (%)
- -
1
1
2
2
3
5
7
11
14
11
13
13
Depreciation Expense
- -
-4
-6
-8
-11
-13
-22
-36
-59
-76
-25
-11
-16
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-626.4
-2,267.4
-7,591.02
-3,501.25
-757.31
-918.29
-1,516.39
-2,047.94
-260.5
-102.23
-31.5
-47.05
Profit Margin (%)
-1
3
13
21
7
7
9
98
51
47
1
18
41
Working Capital
- -
- -
2
3
5
4
3
3
4
2
2
1
1
LT Debt
1
6
17
27
16
25
43
151
109
96
71
102
127
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
1
- -
LT Borrowings
21
1
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
159
163
185
Market Capitalization
333
694
613

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
32
54
80
Cash, Cash Equivalents & STI
25
81
73
Accounts Receivable, Net
7
3
7
Inventories
- -
- -
- -
Total Current Liabilities
15
35
39
Payables & Accruals
- -
- -
- -
ST Debt
- -
1
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
55.4%
45.22%
43.15%
Free Cash Flow
27.66%
3.39%
-51.95%
Net Income, GAAP
24.04%
7.42%
-54.27%
Sales/Revenue/Turnover
153.59%
195.53%
48.39%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8
6
6
5
24
2025
3
3
- -
30
36
2026
2
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.04
-0.03
-0.09
-0.18
2025
-0.06
-0.04
-0.08
0.1
-0.07
2026
-0.08
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
ECO Animal Health Group plc (EAH.L)
Orchid Ventures, Inc. (ORVRF)
TerrAscend Corp. (TSND.TO)
Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS)
Exactus, Inc. (EXDI)
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS.NS)
Business
Nanexa AB (publ) (NANEXA.ST) is a Sweden-based pharmaceutical company specializing in the development of long-acting injectable drug products utilizing its proprietary PharmaShell drug delivery platform, which employs atomic layer deposition technology to enable controlled release of active pharmaceutical ingredients from high drug load formulations; the platform supports applications for small molecules, peptides, proteins, and monoclonal antibodies across indications including type 2 diabetes, obesity, oncology, and other chronic conditions. Founded in 2007 and headquartered in Uppsala, Sweden, the company operates primarily in the Nordic countries, Europe, and North America, advancing its own pipeline projects—NEX-22, a once-monthly depot formulation of liraglutide (GLP-1 analogue) that completed Phase I trials in 2025 demonstrating exposure up to 36 days with good tolerability and no significant gastrointestinal side effects; NEX-18, a depot formulation of azacitidine for myelodysplastic syndrome; and NEX-20, a depot formulation of lenalidomide for multiple myeloma—while licensing PharmaShell to pharmaceutical partners for custom depot formulations. Nanexa maintains ongoing collaborations with major pharmaceutical companies including Novo Nordisk, its largest shareholder, under an exclusivity and evaluation agreement generating milestone payments, and AstraZeneca; recent developments include extension of a feasibility agreement with a major unnamed pharmaceutical company in August 2025 to explore PharmaShell long-acting formulations in a multi-billion USD market, receipt of a Japanese patent approval for a specific PharmaShell structure in September 2025 alongside three new patent applications, appointment of Bridget Lacey as Chief Business Officer in April 2025, termination of the collaboration with Applied Materials in May 2025 yielding a USD 750,000 payment and full revenue retention on future licenses, selection as a finalist in the Fierce Innovation Awards Life Sciences Edition 2025 for Drug Delivery Technology, and a directed share issue and loan raising SEK 55 million earlier in 2025 to fund operations through Q1 2026.